Sverige - svenska - Läkemedelsverket (Medical Products Agency)

panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam

Europeiska unionen - svenska - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversering av neuromuskulär blockad som induceras av rocuronium eller vekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

panpharma sa - paracetamol - infusionsvätska, lösning - 10 mg/ml - glukosmonohydrat hjälpämne; paracetamol 10 mg aktiv substans - paracetamol

Europeiska unionen - svenska - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - läkemedel mot obstruktiv lungsjukdom, - budesonid / formoterol teva pharma b. indikeras endast hos vuxna 18 år och äldre. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Europeiska unionen - svenska - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

panpharma sa - gentamicinsulfat - injektions-/infusionsvätska, lösning - 40 mg/ml - gentamicinsulfat 67,8 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

merz pharmaceuticals gmbh   - memantinhydroklorid - alzheimers sjukdom - andra anti-demensmedel - behandling av patienter med måttlig till svår alzheimers sjukdom.

Europeiska unionen - svenska - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andra matsmältningsorgan och ämnesomsättning produkter, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Europeiska unionen - svenska - EMA (European Medicines Agency)

tillotts pharma gmbh - fidaxomicin - clostridiuminfektioner - antidiarrheals, tarm -, antiinflammatoriska / antiinfective agenter - dificlir filmdragerade tabletter är indicerat för behandling av clostridioides difficile-infektioner (cdi) även känd som c. difficile-associerad diarré (cdad) hos vuxna och pediatriska patienter med en kroppsvikt på minst 12. 5 kg. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel. dificlir granulat till oral suspension är indicerat för behandling av clostridioides difficile-infektioner (cdi) även känd som c. difficile-associerad diarré (cdad) hos vuxna och pediatriska patienter från födseln till < 18 år. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiska radioaktiva läkemedel - detta läkemedel är endast för diagnostisk användning. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos vuxna patienter, för att hjälpa till att skilja trolig demens med lewy organ från alzheimers sjukdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.